Literature DB >> 14531507

Use of hypnotic and tranquillising drugs in general practice. Determinants, satisfaction and motivation to stop: the patients' view.

Frans Vissers1, Remy van der Grinten, Frans van der Horst, Arnold Kester, J André Knottnerus.   

Abstract

OBJECTIVE: To know more about the characteristics of long-term users of hypnotic and tranquillising drugs in a primary health care area in The Netherlands.
DESIGN: A questionnaire was applied to users of benzodiazepines and the computerised medical records were analysed.
SETTING: Nine general practices affiliated to the Registration Network Family Practices (RNH) of the University of Maastricht (UM).
SUBJECTS: A sample of 506 users, aged > or = 30 years, was divided into four categories: short-term (< 3 months) users (once-only and episodic) and long-term users (episodic and continuous).
RESULTS: In 1992/93, 81% were long-term users and 42% of these took their drug continuously. All groups investigated had a preponderance of women. Health problems more so than social problems led to use of the drug. Long-term use was associated with older age, depressive behaviour in handling problems, a higher score on the medicine addiction index, problems with children or housing, and satisfaction with the effects of the drug.
CONCLUSION: Most people taking benzodiazepines are long-term users. Age, depressive behaviour, addiction, satisfaction and problems with children or housing are risk factors for long-term use. Gender is not risk factor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531507     DOI: 10.1080/02813430310005145

Source DB:  PubMed          Journal:  Scand J Prim Health Care        ISSN: 0281-3432            Impact factor:   2.581


  1 in total

1.  A benzodiazepine discontinuation programme does not increase the frequency of contacts with the family practice.

Authors:  Wim Gorgels; Richard Oude Voshaar; Audrey Mol; Eloy Van De Lisdonk; Jan Mulder; Henk Van Den Hoogen; Anton Van Balkom; Marinus Breteler; Frans Zitman
Journal:  Scand J Prim Health Care       Date:  2008       Impact factor: 2.581

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.